Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma.
Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P.
J Clin Oncol. 2012 Feb 20;30(6):e76-8. Epub 2011 Dec 27. No abstract available.
Related citations
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM.
J Clin Oncol. 2012 Jan 20;30(3):322-8. Epub 2011 Dec 19.
Major response to everolimus in melanoma with acquired imatinib resistance.
Si L, Xu X, Kong Y, Flaherty KT, Chi Z, Cui C, Sheng X, Li S, Dai J, Yu W, Guo J.
J Clin Oncol. 2012 Feb 1;30(4):e37-40. Epub 2011 Dec 12. No abstract available.
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O'Day SJ.
J Clin Oncol. 2012 Jan 1;30(1):34-41. Epub 2011 Nov 28.
Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.
Vogel WV, Guislain A, Kvistborg P, Schumacher TN, Haanen JB, Blank CU.
J Clin Oncol. 2012 Jan 10;30(2):e7-e10. Epub 2011 Nov 28. No abstract available.
Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma.
Turner RM, Bell KJ, Morton RL, Hayen A, Francken AB, Howard K, Armstrong B, Thompson JF, Irwig L.
J Clin Oncol. 2011 Dec 10;29(35):4641-6. Epub 2011 Nov 7.
Individualizing follow-up for patients with early-stage melanoma.
Sondak VK, Leachman SA.
J Clin Oncol. 2011 Dec 10;29(35):4606-8. Epub 2011 Nov 7. No abstract available.
Uveal melanoma and BRCA1/BRCA2 genes: a relationship that needs further investigation.
Cruz C, Teule A, Caminal JM, Blanco I, Piulats JM.
J Clin Oncol. 2011 Dec 1;29(34):e827-9. Epub 2011 Oct 24. No abstract available.
Treatment of locally recurrent mucosal melanoma with topical imiquimod.
Smyth EC, Flavin M, Pulitzer MP, Gardner GJ, Costantino PD, Chi DS, Bogatch K, Chapman PB, Wolchok JD, Schwartz GK, Carvajal RD.
J Clin Oncol. 2011 Nov 20;29(33):e809-11. Epub 2011 Oct 17. No abstract available.
Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma.
Burke MM, Kluger HM, Golden M, Heller KN, Hoos A, Sznol M.
J Clin Oncol. 2011 Nov 10;29(32):e792-4. Epub 2011 Oct 11. No abstract available.
T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma.
Del Vecchio M, Mortarini R, Tragni G, Di Guardo L, Bersani I, Di Tolla G, Agustoni F, Colonna V, Weber JS, Anichini A.
J Clin Oncol. 2011 Nov 10;29(32):e783-8. Epub 2011 Oct 11. No abstract available.
Melanoma staging: implications of histologic sectioning procedures.
Pusiol T, Morichetti D, Zorzi MG, Piscioli F.
J Clin Oncol. 2011 Oct 10;29(29):3943-4. Epub 2011 Sep 6. No abstract available.
Parameters predicting prognosis in melanoma sentinel nodes.
Satzger I, Meier A, Alter M, Kapp A, Gutzmer R.
J Clin Oncol. 2011 Sep 10;29(26):3588-90; author reply 3590-1. Epub 2011 Aug 1. No abstract available.
False-positive positron emission tomography in patients with history of malignancy.
Lindskog DM, Nikkhou K, Talusan P.
J Clin Oncol. 2011 Jul 1;29(19):e582-5. Epub 2011 Apr 18. No abstract available.
Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial.
Tang JY, Fu T, Leblanc E, Manson JE, Feldman D, Linos E, Vitolins MZ, Zeitouni NC, Larson J, Stefanick ML.
J Clin Oncol. 2011 Aug 1;29(22):3078-84. Epub 2011 Jun 27.
Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW.
J Clin Oncol. 2011 Jul 20;29(21):2924-32. Epub 2011 Jun 20.
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S.
J Clin Oncol. 2011 Jul 20;29(21):2904-9. Epub 2011 Jun 20.
Increased melanoma after regular sunscreen use?
Goldenhersh MA, Koslowsky M.
J Clin Oncol. 2011 Jun 20;29(18):e557-8; author reply e859. Epub 2011 May 2. No abstract available.
Mitotic rate and sentinel lymph node tumor burden topography: integration into melanoma staging and stratification use in clinical trials.
Averbook BJ.
J Clin Oncol. 2011 Jun 1;29(16):2137-41. Epub 2011 Apr 25. No abstract available.
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria.
van der Ploeg AP, van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, Mitra A, Newton-Bishop JA, Cook M, van der Ploeg IM, Nieweg OE, van den Hout MF, van Leeuwen PA, Voit CA, Cataldo F, Testori A, Robert C, Hoekstra HJ, Verhoef C, Spatz A, Eggermont AM.
J Clin Oncol. 2011 Jun 1;29(16):2206-14. Epub 2011 Apr 25.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on